Related Experiment Video
Updated: Jan 28, 2026

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model
Published on: June 3, 2020
Inducible Ift88-deficient mice show features consistent with mild pulmonary hypertension
Selina M Garcia1, Benjamin J Lantz1, Helen J Wagner1
1Cell Biology and Physiology Department, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
None:
Intraflagellar transport protein 88 (IFT88) is essential for primary and motile cilia formation. In murine models and humans, Ift88 mutations contribute to renal cysts, epithelial proliferation and impaired immune responses. In mice, Ift88 knockout (KO) reduces airway cilia, increases airway epithelial proliferation and hyperreactivity, elevates IL-22 and decreases lung T regulatory cells. Pulmonary hypertension (PH) is a deadly disease marked by aberrant metabolism and immunoinflammatory mediators causing vasoconstriction and vascular remodeling. Endothelial-to-mesenchymal transition (EndMT) contributes to PH, and endothelial-specific Ift88 KO promotes endothelial proliferation and EndMT. We hypothesized that global loss of Ift88 causes PH. We assessed PH indices at 2 and 14 weeks postdeletion in tamoxifen-inducible Ift88 KO mice. These mice showed signs of PH, including increased right ventricular systolic pressure, cell proliferation in the walls of resistance arteries, and arterial wall thickening. At the early time point examined, we did not detect evidence of lung inflammation or EndMT. Because this is a tamoxifen-induced global Ift88 KO model, we cannot attribute the PH features to gene deletion in specific vascular cells, nor can we rule out the possibility that tamoxifen administration, global Ift88 deletion, the associated weight gain and food restriction may have influenced cardiovascular physiology in these mice.
More Related Videos
04:54Invasive Hemodynamic Assessment for the Right Ventricular System and Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
Published on: October 24, 2019
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...